{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:38:51Z","timestamp":1777855131070,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"DCI"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Empiric antimicrobial selection in orthotopic heart transplantation (OHT) is critically important as post-operative infections are a significant cause of morbidity and mortality. While variability of antimicrobial selection exists between centers, both combinations of vancomycin and piperacillin-tazobactam (VPT) and vancomycin and cefepime (VC) are frequently used. VPT drug combination has been associated with increased risk of acute kidney injury (AKI) in multiple reports. Our study aimed to evaluate the infectious impact of changing the empiric antimicrobial selection from VPT to VC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a single-center study in patients who underwent OHT at the Medical University of South Carolina (MUSC) from 2015 through 2021 (n=120). As part of a quality improvement measure, the empiric intraoperative antimicrobial therapy was transitioned from VPT (n=48) to VC (n=72) on 6\/20\/2019, providing a prospective setting to investigate infectious outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 10.4% of patients who received VPT had a positive culture within 30 days of OHT, compared to 9.7% of patients who received VC (p=0.781). All positive cultures were reviewed and deemed to be clinically significant infections. No significant difference in the site of culture positivity was identified between groups (p=0.487). Among patients who developed postoperative infection, there was a trend toward a longer time to infection in patients receiving VPT (median 28 days) than VC (median 14 days), p=0.08.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Culture-positive infections within 30 days post-OHT were similar between patients receiving empiric intraoperative VPT and those receiving VC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-12788-8","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T13:51:54Z","timestamp":1774101114000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Infectious consequences of antimicrobial change from vancomycin-piperacillin\/ tazobactam to vancomycin-cefepime in the prevention of AKI during orthotopic heart transplantation"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0987-2142","authenticated-orcid":false,"given":"Ashley L.","family":"Golbus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4611-0670","authenticated-orcid":false,"given":"Courtney E.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed","family":"Quadri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4093-2200","authenticated-orcid":false,"given":"Rupak","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8112-8345","authenticated-orcid":false,"given":"Arman","family":"Killic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9045-7722","authenticated-orcid":false,"given":"Ryan J.","family":"Tedford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8585-2787","authenticated-orcid":false,"given":"Blaithin A.","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"issue":"6","key":"12788_CR1","doi-asserted-by":"publisher","first-page":"e14296","DOI":"10.1111\/ctr.14296","volume":"35","author":"BM Jocher","year":"2021","unstructured":"Jocher BM, Schilling JD, Fischer I, et al. Acute kidney injury post-heart transplant: an analysis of peri-operative risk factors. Clin Transpl. 2021;35(6):e14296.","journal-title":"Clin Transpl"},{"key":"12788_CR2","first-page":"1","volume":"2","author":"KDI Global","year":"2012","unstructured":"Global KDI, Group OKAKIW. KDIGO clinical practice guidelines for acute kidney injury. Kidney Inter Suppl. 2012;2:1\u2013138.","journal-title":"Kidney Inter Suppl"},{"issue":"1","key":"12788_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/jac\/dkae410","volume":"80","author":"K Pan","year":"2025","unstructured":"Pan K, Li R, Li Y, Ding X, Li X, Lv Q. Vancomycin combined with piperacillin\/tazobactam increases the risk of acute kidney injury compared with Vancomycin plus other anti-pseudomonal beta-lactams: a systematic review and network meta-analysis. J Antimicrob Chemother. 2025;80(1):47\u201358.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"12788_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.chest.2023.03.046","volume":"164","author":"AY Chen","year":"2023","unstructured":"Chen AY, Deng CY, Calvachi-Prieto P, et al. A Large-Scale multicenter retrospective study on nephrotoxicity associated with empiric Broad-Spectrum antibiotics in critically ill patients. Chest. 2023;164(2):355\u201368.","journal-title":"Chest"},{"issue":"9","key":"12788_CR5","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s00134-022-06811-0","volume":"48","author":"TA Miano","year":"2022","unstructured":"Miano TA, Hennessy S, Yang W, et al. Association of Vancomycin plus piperacillin-tazobactam with early changes in creatinine versus Cystatin C in critically ill adults: a prospective cohort study. Intensive Care Med. 2022;48(9):1144\u201355.","journal-title":"Intensive Care Med"},{"issue":"7","key":"12788_CR6","doi-asserted-by":"publisher","first-page":"e70213","DOI":"10.1111\/ctr.70213","volume":"39","author":"AL Golbus","year":"2025","unstructured":"Golbus AL, Quadri S, Park E, et al. Transition from intraoperative Vancomycin-Piperacillin Tazobactam to Vancomycin\u2010Cefepime does not change acute kidney injury or renal recovery outcomes in patients undergoing heart transplantation. Clin Transplant. 2025;39(7):e70213.","journal-title":"Clin Transplant"},{"issue":"4","key":"12788_CR7","doi-asserted-by":"publisher","first-page":"e13104","DOI":"10.1111\/tid.13104","volume":"21","author":"P Fern\u00e1ndez-Ugidos","year":"2019","unstructured":"Fern\u00e1ndez-Ugidos P, Barge\u2010Caballero E, G\u00f3mez\u2010L\u00f3pez R, et al. In\u2010hospital postoperative infection after heart transplantation: risk factors and development of a novel predictive score. Transpl Infect Disease. 2019;21(4):e13104.","journal-title":"Transpl Infect Disease"},{"issue":"2","key":"12788_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1089\/sur.2019.073","volume":"21","author":"R G\u00f3mez-L\u00f3pez","year":"2019","unstructured":"G\u00f3mez-L\u00f3pez R, Barge-Caballero E, Fern\u00e1ndez-Ugidos P, et al. In-Hospital Post-Operative infection after heart transplantation: Epidemiology, clinical Management, and outcome. Surg Infect. 2019;21(2):179\u201391.","journal-title":"Surg Infect"},{"issue":"7","key":"12788_CR9","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/phar.1442","volume":"34","author":"LD Burgess","year":"2014","unstructured":"Burgess LD, Drew RH. Comparison of the incidence of Vancomycin-Induced nephrotoxicity in hospitalized patients with and without concomitant Piperacillin-Tazobactam. Pharmacother J Hum Pharmacol Drug Ther. 2014;34(7):670\u20136.","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"issue":"6","key":"12788_CR10","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1053\/j.jvca.2012.04.021","volume":"26","author":"ME Cove","year":"2012","unstructured":"Cove ME, Spelman DW, MacLaren G. Infectious complications of cardiac surgery: a clinical review. J Cardiothorac Vasc Anesth. 2012;26(6):1094\u2013100.","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"2","key":"12788_CR11","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1128\/AAC.00495-07","volume":"52","author":"KW Garey","year":"2008","unstructured":"Garey KW, Lai D, Dao-Tran TK, Gentry LO, Hwang LY, Davis BR. Interrupted time series analysis of Vancomycin compared to Cefuroxime for surgical prophylaxis in patients undergoing cardiac surgery. Antimicrob Agents Chemother. 2008;52(2):446\u201351.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"12788_CR12","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1399-3062.2008.00316.x","volume":"10","author":"A Ramos","year":"2008","unstructured":"Ramos A, Asensio A, Mu\u00f1ez E, et al. Incisional surgical infection in heart transplantation. Transpl Infect Disease. 2008;10(4):298\u2013302.","journal-title":"Transpl Infect Disease"},{"key":"12788_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13613-019-0490-2","volume":"9","author":"S Pons","year":"2019","unstructured":"Pons S, Sonneville R, Bouadma L, et al. Infectious complications following heart transplantation in the era of high-priority allocation and extracorporeal membrane oxygenation. Ann Intensiv Care. 2019;9:1\u20139.","journal-title":"Ann Intensiv Care"},{"key":"12788_CR14","doi-asserted-by":"crossref","unstructured":"Multani A, Moayedi Y, Puing A, et al. Recent trends of infectious complications following heart transplantation. Transplantation 2020;104(10).","DOI":"10.1097\/TP.0000000000003307"},{"issue":"5","key":"12788_CR15","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1089\/sur.2017.295","volume":"19","author":"KC Shultes","year":"2018","unstructured":"Shultes KC, Shuster JE, Micek S, et al. Outcomes and predictors of early infection after heart transplantation. Surg Infect. 2018;19(5):516\u201322.","journal-title":"Surg Infect"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12788-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12788-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12788-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:19:35Z","timestamp":1777504775000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12788-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12788"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12788-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project was submitted to the local IRB at the Medical University of South Carolina and granted exempt status, as it was determined to be quality improvement as part of an effort to improve AKI rates in patients undergoing heart transplantation and was therefore not subject to IRB review or approval. Consent to participate was waived as this project was determined to be quality improvement. This study adhered to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AG, EP, and CH report no disclosures. AK reports no disclosures directly relevant to the manuscript.\u00a0 AK receives research funding from the National Heart, Lung, and Blood Institute.\u00a0 AK reports consulting and speaking relationships with Abiomed, Abbott, 3ive, and LivaNova. AK is a national principal investigator on an industry sponsored clinical trial with Abbott. RT reports no disclosures relevant to this manuscript.\u00a0 RT is Deputy Editor for the Journal of Heart and Lung Transplantation.\u00a0 \u00a0RT reports general disclosures to include consulting relationships with and receiving honorarium\/consulting fees from Abbott, Acorai, Adona, Aria CV Inc., Acceleron\/Merck, Alleviant, Boston Scientific, Cytokinetics, Endotronix, Edwards LifeSciences, Gradient, Medtronic, Merck, Morphic Therapeutics, Pulmovant, Restore Medical, Tempus AI, and United Therapeutics. RT serves on steering committee for Abbott, Edwards, Endotronix, Gradient, \u00a0Merck and Tempus AI as well as a research advisory board for \u200bAbiomed. BAM reports no disclosures relevant to this manuscript. BAM reports consulting relationships with Vantive Corporate.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"854"}}